Fc receptor like 1Genealiases: CD307a · FCRH1 · IFGP1 · IRTA5
Q-omics provides the consensus-scored FCRL1 profile across patient tissues and cancer cell-line models. FCRL1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FCRL1 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, FCRL1 RNA expression shows 17,590 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where FCRL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCRL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCRL1 survival associations across molecular data types. FCRL1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCRL1 RNA expression–survival associations across cancer types. High FCRL1 expression shows unfavorable associations in UVM, but favorable associations in HNSC, LUAD, SKCM, BRCA and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FCRL1 RNA expression.
This table summarizes FCRL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FCRL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCRL1 shows lower tumor expression in COAD, LUSC, BLCA, THCA and LUAD and higher tumor expression in BRCA. The COAD box plot shows higher FCRL1 RNA expression in normal versus tumor tissue (log2 FC = −0.757, t-test p < 0.001).
This table shows molecular features associated with FCRL1 in patient tissues and cancer cell lines. In patient samples, FCRL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FCRL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
